EXCLUSIVE: BeyondSpring CEO Talks Better-Than-Expected Trial Results That Sent The Stock Soaring
BeyondSpring Inc (NASDAQ: BYSI) recently announced positive topline data from its DUBLIN-3 registrational trial in plinabulin in combination with docetaxel for the treatment of second and third line non-small cell lung cancer.
